Idiopathic Retroperitoneal Fibrosis — A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
Citation(s)
A Prospective, Controlled, Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis